Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Pharmanson Consulting AB
AB
Active
Org 5593650830
John Ericssonsgatan 1
Business and other management consultancy activities · NACE 7020
Est. 2022
1-4 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
SEK 200K
+102% vs 2024
EBITDA margin
3.5%
+126% vs 2024
Equity ratio
13.5%
Financial strength
Net profit 2025
SEK 1K
+105% vs 2024
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2023
0M
0%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
SEK 200K
+102%
EBITDA
SEK 7K
+126%
Net profit
SEK 1K
+105%
Total assets
SEK 222K
+231%
Equity
SEK 30K
+0%
Employees
—
—
Company information
Legal name
Pharmanson Consulting AB
Org number
5593650830
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
11 februari 2022
Share capital
SEK 25 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-06-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska bedriva konsultverksamhet inom organisationsutveckling.
Contact
Address
John Ericssonsgatan 1
Email
pharmanson@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Business and other management consultancy activities
Companies in Danderyd
All Sweden companies
Revenue
SEK millions
0M
1M
1M
2M
2M
2M
2023
0M
2024
0M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2023
0M
2024
0M
2025
Income statement
SEK thousands
Item
2023
2024
2025
Revenue
1 854
99
200
Staff expenses
—
—
—
EBITDA
254
−27
7
Depreciation & amort.
−0
−0
−0
EBIT
254
−27
7
Net financials
—
10
—
Profit before tax
255
−18
7
Tax
−60
−3
−6
Net profit
195
−21
1
Balance sheet
SEK thousands
Item
2023
2024
2025
Total assets
900
67
222
Equity
220
30
30
Long-term debt
0
0
0
Short-term debt
680
37
192
Total debt
680
37
192
Financial ratios
5-year trend
EBITDA margin
3.5%
This company
15.8%
Market median
-78% vs market
2023
2025
Equity ratio
13.5%
This company
38.2%
Market median
-65% vs market
2023
2025
Return on equity
3.3%
This company
18.4%
Market median
-82% vs market
2023
2025
Net profit margin
0.5%
This company
8.1%
Market median
-94% vs market
2023
2025
Asset turnover
0.90×
This company
1.12×
Market median
+20% vs market
2023
2025
Debt / equity
6.40×
This company
0.62×
Market median
-932% vs market
2023
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-07-01 – 2025-06-30
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-07-01 – 2024-06-30
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-02-01 – 2023-06-30
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
JB
Julia Birgitta Miriam Pharmanson
Deputy Board Member
2022
HB
Helena Birgitta Pharmanson
Board of Directors
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Pharmanson Consulting AB also hold positions in
0
other companies.
Person
Role here
Other companies
Julia Birgitta Miriam Pharmanson
Deputy Board Member
0 companies
Helena Birgitta Pharmanson
Board of Directors
0 companies